Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors

Details for Australian Patent Application No. 2005292152 (hide)

Owner Amgen Inc

Inventors Falsey, James Richard; Kim, Joseph L.; Deak, Holly L.; Chakrabarti, Partha P.; Cee, Victor J.; Demorin, Frenel F.; Harmange, Jean-Christophe; Albrecht, Brian K.; Chaffee, Stuart C.; Liu, Gang; Masse, Craig E.; Tasker, Andrew; Xu, Shimin; Rzasa, Robert M.; GeunsMeyer, Stephanie D.; McGowan, David C.; Herberich, Bradley J.; Hodous, Brian L.; Cao, Guo-Qiang; Bemis, Jean E.; Reed, Anthony; Smith, Adrian Leonard; Graceffa, Russell; Bellon, Steven; Habgood, Gregory J.; Patel, Vinod F.; Zhang, Dawei; Martin, Matt

Agent Shelston IP

Pub. Number AU-B-2005292152

PCT Pub. Number WO2006/039718

Priority 60/615,535 01.10.04 US; 11/240,590 30.09.05 US

Filing date 3 October 2005

Wipo publication date 13 April 2006

Acceptance publication date 12 August 2010

International Classifications

C07D 239/84 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 215/12 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

C07D 239/95 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/10 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/04 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 409/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 409/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 409/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

26 April 2007 PCT application entered the National Phase

  PCT publication WO2006/039718 Priority application(s): WO2006/039718

12 August 2010 Application Accepted

  Published as AU-B-2005292152

9 December 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005292162-3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection

2005292145-Conveniently implantable sustained release drug compositions